Prasco Laboratories is releasing an authorized generic version of Vancocin Hydrochloride Capsules.


Prasco Laboratories, Vancocin Hydrochloride Capsules, authorized generic, ViroPharma, C. difficile-associated diarrhea, CDAD, enterocolitis, Chris Arington, Dan Soland


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Prasco to roll out vancomycin capsules

April 11th, 2012

CINCINNATI – Prasco Laboratories is releasing an authorized generic version of Vancocin Hydrochloride Capsules.

Prasco said Wednesday that it will exclusively sell and distribute the authorized generic, which comes in strengths of 125 mg and 250 mg, as part of a distribution and supply pact with ViroPharma Inc.

"We are pleased to have established this relationship with ViroPharma," stated Prasco chief executive officer Chris Arington. "Consumers and pharmacists will have as one of their prescription drug choices an authorized generic product that provides the identical product, quality, reliability and experience as the brand."

Vancomycin hydrochloride capsules are indicated for the treatment of C. difficile-associated diarrhea (CDAD). The drug is also used for the treatment of enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

"Prasco is the industry leader in authorized generics, and we are pleased to have partnered with them on this project," commented Dan Soland, ViroPharma's chief operating officer. "Through this partnership, patients suffering from dangerous C. difficile infections will now have access to a generic formulation of Vancocin that is identical to the brand and proven through decades of use to be a high-quality treatment for this potentially deadly disease."

Advertisement